UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________________________________________________________________

FORM 8-K

________________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~June~~July 214, 2026

________________________________________________________________________________________________

Crescent Biopharma, Inc.

(Exact Name of Registrant as Specified in Charter)

________________________________________________________________________________________________


Cayman Islands	001-36177	06-1686563
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

300 Fifth Avenue Waltham, MA		02451
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 430-5595

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

________________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Ordinary Shares, $0.001 par value per share

CBIO

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 52.~~07 Submission~~02 Results of ~~Matters~~Operations toand aFinancial ~~Vote of Security Holders~~Condition.

~~On June 2, 2026,~~ Crescent Biopharma, Inc. (the “Company”) ~~held~~is ~~its~~providing ~~annual general meeting of shareholders (~~the ~~“Annual~~following ~~Meeting”)~~financial information. AtAs ~~the close~~ of ~~business~~June ~~on April 7~~30, 2026, the ~~record~~Company ~~date~~estimates ~~for~~that ~~the~~its ~~Annual~~cash ~~Meeting~~and ~~(the~~cash ~~“Record~~equivalents ~~Date”), 27,571,935 ordinary shares, par value $0.001 per share (“Ordinary Shares”),~~ were ~~issued~~approximately ~~and outstanding, and 2,890 Series A non-voting convertible preferred shares, par value~~ $0171.~~001~~6 ~~per share (“Series A Preferred Shares”), were issued and outstanding~~million. Each Ordinary Share was entitled to one vote per share for the election of Susan Moran, M.D., MSCE and one vote on each of proposals 3, 4 and 5. The holders of each Series A Preferred Share were entitled to 1,000 votes per share, voting as a separate class for the election of Jonathan Violin, Ph.D. and voting together with the holders of Ordinary Shares as a single class for the election of Susan Moran, M.D., MSCE, and were not entitled to vote on any other proposal. The following are the voting results for the proposals considered and voted upon at the Annual Meeting, each of which was described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 21, 2026.

~~Proposal~~The ~~No.~~cash 1A and ~~Proposal~~cash ~~No.~~equivalents 1Binformation -above ~~Election~~is ofbased ~~two~~on ~~Class~~preliminary IIunaudited ~~directors~~information toand ~~serve~~management ~~until~~estimates for the ~~Company’s~~quarter ~~2029~~ended ~~Annual~~June ~~General~~30, ~~Meeting~~2026, ofis ~~Shareholders~~not ~~and~~a ~~until~~comprehensive ~~their~~statement ~~respective~~of ~~successors~~our ~~have~~financial ~~been~~results ~~duly~~as ~~elected~~of and ~~qualified~~for orthe ~~until~~quarter ~~their~~ended ~~earlier~~June ~~death~~30, ~~resignation~~2026, ~~disqualification~~and oris ~~removal~~subject to completion of the Company’s financial closing procedures.

	Votes FOR	Votes WITHHELD	Broker Non-Votes
Jonathan Violin, Ph.D. (Proposal No. 1A)	2,890,000	0	0
Susan Moran, M.D., MSCE (Proposal No. 1B)	21,401,136	136,056	2,403,515

The preliminary financial data included in this current report has been prepared by, and is the responsibility of, the Company's management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto.

~~Proposal~~Pursuant ~~No.~~to the rules and regulations of the SEC, the information provided in this Item 2.02 of this Form 8-K ~~Ratification~~shall be deemed “filed” for purposes of ~~the~~Section ~~appointment~~18 of ~~PricewaterhouseCoopers~~the ~~LLP~~Securities Exchange Act of 1934, as amended (the ~~Company’s~~“Exchange ~~independent~~Act”), ~~registered~~and ~~public~~shall ~~accounting~~be ~~firm~~deemed ~~for~~to be incorporated by reference in any filing under the ~~fiscal~~Securities ~~year~~Act ~~ending~~of ~~December~~1933, 31as amended, ~~2026~~or the Exchange Act, unless otherwise expressly set forth by specific reference in such a filing.

Votes FOR						Votes AGAINST						Votes ABSTAINED						Broker Non-Votes
21,049,101						1,452						154						0

Forward-Looking Statements

~~Proposal~~The NoCompany cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. 3The forward-looking ~~Approval,~~statements are based on athe ~~non-binding~~Company’s ~~advisory~~current ~~basis~~beliefs and expectations and include, but are not limited to: statements regarding the preliminary estimate of the ~~compensation~~Company’s cash and cash equivalents as of June 30, 2026. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company’s ~~named~~business, ~~executive~~including, ~~officers~~without limitation: our actual results for the second quarter or full year of 2026 may differ materially from our preliminary estimates as a result of changes to assumptions and estimates, the completion of review of internal controls over financial reporting or other quarter-end and year-end procedures; and other risks described in the Company’s prior filings with the SEC, including under the heading “Risk Factors” in its annual report on Form 10-K for the year ended December 31, 2025, its quarterly report on Form 10-Q for the quarter ended March 31, 2026, and any subsequent filings with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof, except as required by law.

Votes FOR						Votes AGAINST						Votes ABSTAINED						Broker Non-Votes
18,346,099						300,217						876						2,403,515

Proposal No. 4 - Approval, on a non-binding advisory basis, of the frequency of future advisory votes to approve the compensation of the Company’s named executive officers.

1 YEAR						2 YEARS						3 YEARS						Votes ABSTAINED						Broker Non-Votes
18,644,881						903						887						521						2,403,515

Based on the foregoing votes, each of Jonathan Violin, Ph.D. and Susan Moran, M.D., MSCE was elected as a Class II director, Proposal 2 and Proposal 3 were approved, and shareholders recommended a one year frequency for future advisory votes to approve named executive officer compensation.

Based on the foregoing voting results and consistent with the recommendation of the Board of Directors of the Company (the “Board”), the Board has determined to hold an advisory vote on the compensation of the Company’s named executive officers every year until the next advisory vote regarding the frequency of future advisory votes on the compensation of the Company’s named executive officers is submitted to the shareholders or the Board otherwise determines that a different frequency for such advisory votes is in the best interest of the Company and its shareholders.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CRESCENT BIOPHARMA, INC.

Date: June 3, 2026

By:

/s/ Joshua Brumm

Date: July 14, 2026

By:

/s/ Joshua Brumm

Name:

Joshua Brumm

Title:

Chief Executive Officer

Filing Compare · CRESCENT BIOPHARMA, INC.